Follow-up study comparing two rituximab options in new DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows people who already took part in an earlier Phase III trial to see how well two rituximab medicines work over time. It looks at outcomes like how long participants live and how long the disease stays under control, and may help confirm whether the biosimilar is comparable to the original.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously joined the Phase III trial NCT02787239.
- You are alive and able to take part in follow-up.
- You are willing to participate in follow-up visits or updates.
- Your study doctor agrees you are suitable to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This trial tests a new drug, SHR-A1912, combined with standard chemotherapy (R-GemOx) for people with diffuse large B-cell lymphoma (DLBCL) that has returned or not improved after at least one prior treatment. It aims to see if the combination works better than chemotherapy alone.
This study compares three different drug combinations for people with untreated DLBCL. One group gets a standard combination (pola-RCHP), another gets that plus a targeted pill (like orelabrutinib or venetoclax), and a third gets the standard chemo without the targeted antibody. The goal is to see which approach works best and is safest.
This Phase 2 trial tests a PD-1 antibody (anti–PD-1) added to standard R-CHOP chemotherapy for certain people with diffuse large B-cell lymphoma (DLBCL) who have a p53 mutation and tumor PD-L1 expression. It may help shrink lymphoma more effectively when these tumor markers are present.
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.